Enlivex Receives FDA IND Clearance for Phase 2b Trial of Allocetra in Age-Related Knee Osteoarthritis
核心洞察
Enlivex (搜索) Ltd. received FDA Investigational New Drug clearance for Allocetra™, enabling a global Phase 2b trial in moderate-to-severe age-related knee osteoarthritis.
The approval follows positive Phase 1/2a results from 134 patients showing robust, durable, and statistically significant treatment effects lasting at least six months.
Knee osteoarthritis affects over 32 million Americans today and is projected to impact 78 million by 2040, with no approved disease-modifying therapies currently available.
The U.S. Food and Drug Administration has cleared Enlivex (搜索) Ltd.'s Investigational New Drug application for Allocetra™, the company's clinical-stage immunotherapy for treating patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis. The clearance enables the Israel-based quality longevity company to initiate a global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial.
The FDA approval represents the first regulatory clearance obtained by Enlivex (搜索) following implementation of its dual-engine value creation model, which combines clinical-stage quality longevity program development with a prediction markets treasury strategy.
Strong Phase 1/2a Foundation
The IND clearance follows positive 3- and 6-month data from Enlivex (搜索)'s Phase 1/2a multicenter, randomized, double-blind, placebo-controlled clinical trial that enrolled 134 patients. The study demonstrated a robust, durable, clinically meaningful, and statistically significant treatment effect in older patients with knee osteoarthritis, with increasing benefit observed in older patient populations.
"In our previous clinical study, Allocetra™ demonstrated a robust, durable, and clinically meaningful treatment effect lasting at least six months, with increasing benefit observed in older patient populations," said Oren Hershkovitz, Ph.D, CEO of Enlivex (搜索).
Addressing Significant Unmet Medical Need
Knee osteoarthritis represents one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. The disease burden increases sharply with age, affecting roughly 30% of the population by age 60, with about half of knee osteoarthritis patients being 60 years and older.
Currently, no approved disease-modifying therapies exist for knee osteoarthritis. Treatment options remain largely limited to pain relief, intra-articular steroids, or surgery. This demographic is expanding with global aging trends, underscoring the need for new, durable therapies.
Phase 2b Trial Design
The upcoming Phase 2b trial has been designed to be statistically powered to evaluate key efficacy endpoints, including change from baseline in pain and physical function compared with placebo, measured at three- and six-months following treatment. The study will assess the efficacy and safety of intra-articular injections of Allocetra™ in patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis.
Additional endpoints include changes in quality-of-life measures and functional mobility assessments. The trial design focuses on evaluating Allocetra™'s potential to address what Hershkovitz described as "a major unmet medical need for elderly patients suffering from knee osteoarthritis."
Company Profile
Enlivex (搜索) operates as a quality longevity company powered by a prediction markets treasury. Beyond its clinical programs, the company operates a prediction markets treasury strategy built around the RAIN protocol, described as the leading decentralized prediction markets infrastructure on Arbitrum. This dual-engine structure combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.
Allocetra™ represents an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. The therapy's mechanism targets the inflammatory pathways that contribute to joint degeneration in aging populations.